Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Dec 1991

Triostat: FDA approved

Treatment of myxedema coma/precoma.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

Triostat

SmithKline Beecham Pharmaceuticals

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Triostat

(Liothyronine sodium injection)Orphan drug

SmithKline Beecham Pharmaceuticals

Approved Dec 1991

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome.
Search all trials →
Search clinical trials for Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome

Recent News & Research

No recent news articles indexed yet for Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome.
Search PubMed for Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome

Browse all Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome news →

Specialist Network

No specialists currently listed for Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome.

View all Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome specialists →

Quick Actions